Delivery Order SPE2DB20D2104-SPE2DB25FMSLF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency awarded a $6,199.32 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on September 17, 2025, with completion scheduled for September 18, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and...
- The Defense Logistics Agency awarded a delivery order valued at $8,137.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement supporting federal pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a $1,599.24 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract, with an ultimate completion date of June 17, 2025. This non-set-aside award was competitively procured and represents a single delivery order fulfilling federal pharmaceutical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a $6,239.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count unit of use packaging). The contract was awarded on August 29, 2025, with an ultimate completion date of September 2, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $5,737.25 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order as part of its critical role in the federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $9,926.00 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.50 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract carries an ultimate completion date of September 5, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this medical supply...
- The Defense Logistics Agency awarded a $8,391.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on September 25, 2025, with completion targeted for September 26, 2025. This non-set-aside award reflects a routine pharmaceutical procurement through competitive procedures. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,956.58 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This non-set-aside, firm fixed price delivery order was competitively awarded on August 8, 2025, with an ultimate completion date of August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location....
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMSLFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,671.56 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract. The award was made on June 3, 2025, with an ultimate completion date of June 4, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The contract reflects DLA's strategy to maintain robust pharmaceutical supply chains through established prime vendor relationships with qualified distributors capable of meeting diverse federal medical requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 6/3/25 |